|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1996-6-28
|
|
pubmed:abstractText |
Tadenan (DEBAT, Paris, France) is a pharmaceutical agent used in the treatment of benign prostatic hyperplasia (BPH). The specific aim of this study was to determine if pretreatment of rabbits with Tadenan reduced either the hypertrophic response of the bladder to partial outlet obstruction or the accompanying contractile dysfunction.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
155
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1466-70
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8632612-Adenosine Triphosphate,
pubmed-meshheading:8632612-Animals,
pubmed-meshheading:8632612-Bethanechol,
pubmed-meshheading:8632612-DNA,
pubmed-meshheading:8632612-Fatty Alcohols,
pubmed-meshheading:8632612-Male,
pubmed-meshheading:8632612-Plant Extracts,
pubmed-meshheading:8632612-Potassium Chloride,
pubmed-meshheading:8632612-Rabbits,
pubmed-meshheading:8632612-Urinary Bladder,
pubmed-meshheading:8632612-Urinary Bladder Neck Obstruction
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Protective effect of Tadenan on bladder function secondary to partial outlet obstruction.
|
|
pubmed:affiliation |
Division of Urology, University of Pennsylvania 19104, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
